What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature that provides access to the same valuation methodology used by Fundamental Research Corp for allocating our firm's capital. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is MorphoSys AG stock price today?

MorphoSys AG (MPSYF) is currently trading at $73.27 USD on OTC. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does MorphoSys AG do?

MorphoSys AG operates in the Biotechnology sector within Healthcare. MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling c...

How do I analyze MorphoSys AG stock performance?

Our Snowflake Analysis provides a visual snapshot of MorphoSys AG performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find MorphoSys AG financial statements?

Access MorphoSys AG complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC uses the same proprietary valuation model for public stock analysis that we use for allocating our own firm's capital. This means our fair value estimates are based on the same rigorous, data-driven methodology that institutional investors trust. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About MorphoSys AG

Industry

Biotechnology

Sector

Healthcare

CEO

Arkadius Pichota

Headquarters

Semmelweisstrasse 7, Planegg, DE

Industry

Biotechnology

Sector

Healthcare

CEO

Arkadius Pichota

Headquarters

Semmelweisstrasse 7, Planegg, DE

Description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

MorphoSys AG

MPSYF•OTC

MorphoSys AG

MPSYF•OTC

Market cap

$2.76B

Sentiment

Your view on MPSYF

Mkt Cap

$2.76B

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About MorphoSys AG

Industry: Biotechnology
Sector: Healthcare
CEO: Arkadius Pichota
Headquarters: Semmelweisstrasse 7, Planegg, DE

Industry: Biotechnology
Sector: Healthcare
CEO: Arkadius Pichota
Headquarters: Semmelweisstrasse 7, Planegg, DE

Description

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News